The shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have nearly halved this morning, down 49.8% at $84.90 at last check, after the company's experimental gene therapy to treat Duchene muscular dystrophy (DMD) did not meet the main goal of its study.
Full Story >>
Vote
+18